APLS

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Apellis Pharmaceuticals Inc

NASDAQ | APLS

22.37

USD

+$0.00

(

+0.00%

)

At Close (As of Sep 26, 2025)

$2.81B

Market Cap

-

P/E Ratio

-1.83

EPS

$35.72

52 Week High

$16.10

52 Week Low

HEALTHCARE

Sector

APLS Chart

Recent Chart
Price Action

APLS Technicals

Tags:

APLS Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $664M
Total Revenue $781M
Cost Of Revenue $118M
Costof Goods And Services Sold $118M
Operating Income -$165M
Selling General And Administrative $501M
Research And Development $328M
Operating Expenses $829M
Investment Income Net -
Net Interest Income -$28M
Interest Income $13M
Interest Expense $40M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.8M
Income Before Tax -$197M
Income Tax Expense $1.2M
Interest And Debt Expense -
Net Income From Continuing Operations -$198M
Comprehensive Income Net Of Tax -
Ebit -$156M
Ebitda -$155M
Net Income -$198M

Revenue & Profitability

Earnings Performance

APLS Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $885M
Total Current Assets $789M
Cash And Cash Equivalents At Carrying Value $411M
Cash And Short Term Investments $411M
Inventory $81M
Current Net Receivables $272M
Total Non Current Assets $96M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $25M
Other Non Current Assets -
Total Liabilities $657M
Total Current Liabilities $186M
Current Accounts Payable $39M
Deferred Revenue -
Current Debt -
Short Term Debt $6.8M
Total Non Current Liabilities $471M
Capital Lease Obligations $17M
Long Term Debt $453M
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $470M
Other Current Liabilities $140M
Other Non Current Liabilities $8M
Total Shareholder Equity $229M
Treasury Stock -
Retained Earnings -$3B
Common Stock $12K
Common Stock Shares Outstanding $124M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$88M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $1.8M
Capital Expenditures $403K
Change In Receivables -
Change In Inventory -$11M
Profit Loss -
Cashflow From Investment -$403K
Cashflow From Financing $149M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity $4.5M
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$198M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $664M
Total Revenue $781M
Cost Of Revenue $118M
Costof Goods And Services Sold $118M
Operating Income -$165M
Selling General And Administrative $501M
Research And Development $328M
Operating Expenses $829M
Investment Income Net -
Net Interest Income -$28M
Interest Income $13M
Interest Expense $40M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.8M
Income Before Tax -$197M
Income Tax Expense $1.2M
Interest And Debt Expense -
Net Income From Continuing Operations -$198M
Comprehensive Income Net Of Tax -
Ebit -$156M
Ebitda -$155M
Net Income -$198M

APLS News

APLS Profile

Apellis Pharmaceuticals Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Apellis Pharmaceuticals, Inc. is an innovative clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in therapeutic compounds that target the complement system to address various autoimmune and inflammatory diseases. With a robust portfolio of product candidates, Apellis aims to transform the treatment landscape for patients suffering from these challenging conditions. The company's leading asset highlights its commitment to harnessing novel therapeutic mechanisms, positioning it as a key player in the evolving biopharmaceutical sector.

DVLT
+30.57%
$1.09
INTC
+8.87%
$33.99
GPUS
+19.56%
$0.45
CGBS
-39.47%
$0.03
DFLI
+38.45%
$0.52
SNAP
-0.72%
$8.27
NUAI
+33.33%
$1.84
NVDA
+0.28%
$178.19
CJET
+10.63%
$0.17
F
+3.39%
$12.01
DNN
-3.14%
$2.77
PSTV
+9.60%
$0.61
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
RGTI
-2.86%
$31.18
BIAF
+55.13%
$5.29
YAAS
-8.19%
$0.09
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-5.75%
$7.04
ADAP
+15.74%
$0.14
AAL
-0.70%
$11.31
WOK
-5.22%
$0.08
NEHC
+49.83%
$1.38
RIG
+0.79%
$3.18
IONZ
+5.83%
$4.34
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
BBD
-2.09%
$3.27
MRM
+102.75%
$2.94
QBTS
+1.59%
$26.76
VALE
-1.74%
$10.70
IREN
-9.57%
$41.86
BTG
+1.44%
$4.92
BLMZ
+12.51%
$0.20
QUBT
-2.11%
$20.14
LYT
-16.77%
$0.09
AMZN
-0.93%
$218.15
MARA
+0.37%
$16.13
KVUE
+1.54%
$16.42
CAN
-10.64%
$0.79
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
RXRX
-5.12%
$4.63
AAPL
-0.54%
$255.46
ATCH
-4.22%
$0.79
SOUN
-2.50%
$15.94
PLTR
-0.86%
$177.57
BITF
-5.22%
$2.54
TLRY
-3.36%
$1.14
WBD
-1.36%
$19.51
FCX
+1.14%
$35.74
BMNR
+1.69%
$50.41
RMBL
+60.50%
$3.21
BURU
-3.83%
$0.13
ETHD
-5.95%
$3.95
IXHL
-0.01%
$0.59
SHOT
+12.24%
$0.28
GRAB
-2.24%
$6.11
ADD
-25.47%
$0.05
RR
+2.68%
$4.20
CLSK
-5.32%
$13.68
RIVN
-0.95%
$15.59
ONDS
-1.16%
$7.66
SOFI
-0.49%
$27.98
BULL
+3.55%
$15.16
CVE
+0.36%
$17.76
RAYA
-3.15%
$0.04
SRM
+53.27%
$10.30
ACHR
-0.53%
$9.27
PFE
+0.67%
$23.76
IONQ
-3.09%
$67.28
BB
+6.34%
$4.94
JOBY
+1.63%
$16.12
NOK
-0.42%
$4.66
AMD
-1.12%
$159.46
CRWV
-4.98%
$120.34
CLF
+2.52%
$12.37
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BTE
+2.64%
$2.52
QS
+1.28%
$12.66
WLGS
-5.57%
$0.04
HIMS
+6.39%
$58.38
ABEV
0.00%
$2.29
AQMS
+48.37%
$7.30
MRVL
-0.76%
$83.17
ETWO
0.00%
$3.30
HBAN
+0.57%
$17.42
ORCL
-2.70%
$283.45
HOOD
-0.70%
$121.78
AG
+4.02%
$12.14
AIIO
-15.63%
$2.04
NWTN
-15.63%
$2.04
SDM
-86.40%
$1.85
T
+0.03%
$28.31
OKLO
-7.21%
$110.53
ITUB
+0.55%
$7.24
MU
+0.28%
$157.27
AFMD
-34.94%
$0.18
DVLT
+30.57%
$1.09
INTC
+8.87%
$33.99
GPUS
+19.56%
$0.45
CGBS
-39.47%
$0.03
DFLI
+38.45%
$0.52
SNAP
-0.72%
$8.27
NUAI
+33.33%
$1.84
NVDA
+0.28%
$178.19
CJET
+10.63%
$0.17
F
+3.39%
$12.01
DNN
-3.14%
$2.77
PSTV
+9.60%
$0.61
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
RGTI
-2.86%
$31.18
BIAF
+55.13%
$5.29
YAAS
-8.19%
$0.09
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-5.75%
$7.04
ADAP
+15.74%
$0.14
AAL
-0.70%
$11.31
WOK
-5.22%
$0.08
NEHC
+49.83%
$1.38
RIG
+0.79%
$3.18
IONZ
+5.83%
$4.34
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
BBD
-2.09%
$3.27
MRM
+102.75%
$2.94
QBTS
+1.59%
$26.76
VALE
-1.74%
$10.70
IREN
-9.57%
$41.86
BTG
+1.44%
$4.92
BLMZ
+12.51%
$0.20
QUBT
-2.11%
$20.14
LYT
-16.77%
$0.09
AMZN
-0.93%
$218.15
MARA
+0.37%
$16.13
KVUE
+1.54%
$16.42
CAN
-10.64%
$0.79
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
RXRX
-5.12%
$4.63
AAPL
-0.54%
$255.46
ATCH
-4.22%
$0.79
SOUN
-2.50%
$15.94
PLTR
-0.86%
$177.57
BITF
-5.22%
$2.54
TLRY
-3.36%
$1.14
WBD
-1.36%
$19.51
FCX
+1.14%
$35.74
BMNR
+1.69%
$50.41
RMBL
+60.50%
$3.21
BURU
-3.83%
$0.13
ETHD
-5.95%
$3.95
IXHL
-0.01%
$0.59
SHOT
+12.24%
$0.28
GRAB
-2.24%
$6.11
ADD
-25.47%
$0.05
RR
+2.68%
$4.20
CLSK
-5.32%
$13.68
RIVN
-0.95%
$15.59
ONDS
-1.16%
$7.66
SOFI
-0.49%
$27.98
BULL
+3.55%
$15.16
CVE
+0.36%
$17.76
RAYA
-3.15%
$0.04
SRM
+53.27%
$10.30
ACHR
-0.53%
$9.27
PFE
+0.67%
$23.76
IONQ
-3.09%
$67.28
BB
+6.34%
$4.94
JOBY
+1.63%
$16.12
NOK
-0.42%
$4.66
AMD
-1.12%
$159.46
CRWV
-4.98%
$120.34
CLF
+2.52%
$12.37
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BTE
+2.64%
$2.52
QS
+1.28%
$12.66
WLGS
-5.57%
$0.04
HIMS
+6.39%
$58.38
ABEV
0.00%
$2.29
AQMS
+48.37%
$7.30
MRVL
-0.76%
$83.17
ETWO
0.00%
$3.30
HBAN
+0.57%
$17.42
ORCL
-2.70%
$283.45
HOOD
-0.70%
$121.78
AG
+4.02%
$12.14
AIIO
-15.63%
$2.04
NWTN
-15.63%
$2.04
SDM
-86.40%
$1.85
T
+0.03%
$28.31
OKLO
-7.21%
$110.53
ITUB
+0.55%
$7.24
MU
+0.28%
$157.27
AFMD
-34.94%
$0.18
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.